SCHEMBL4234451

SCHEMBL4234451

COc1ccc(CC(=O)NCc2ccccc2-c2ccsc2C(=O)NCc2ccc(F)cc2F)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.79
KCNK3 O14649 2/20 0.79
KCNK5 O95279 1/20 0.79
KCNK17 Q96T54 1/20 0.79
KCNK9 Q9NPC2 1/20 0.79
KCNH2 Q12809 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 2/20 0.42
ALDH1A1 P00352 1/20 0.42
DGAT2 Q96PD7 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
ERCC1 P07992 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4231667 0.90 KCNA5 (0.79) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL498641 0.88 KCNA5 (1.00) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL4234905 0.84 KCNA5 (0.78) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL726080 0.83 KCNA5 (0.77) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL4231221 0.83 KCNA5 (0.85) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434336 0.80 KCNA5 (0.84) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434391 0.79 KCNA5 (0.83) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434396 0.77 KCNA5 (0.79) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434045 0.76 KCNA5 (0.78) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789620 0.74 KCNA5 (0.74) KCNA5KCNK3KCNK5KCNK17KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149496-A1 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-06-11 US claimed
EP-2012758-A2 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL Sanofi-Aventis Deutschland GmbH (DE) 2009-01-14 EP claimed
WO-2007124849-A2 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-11-08 WO claimed
US-20090149496-A1 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-06-11 US disclosed
US-20090149496-A1 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-06-11 US disclosed
US-20090149496-A1 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-06-11 US disclosed
EP-2012758-A2 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL Sanofi-Aventis Deutschland GmbH (DE) 2009-01-14 EP disclosed
WO-2007124849-A2 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-11-08 WO disclosed
WO-2007124849-A2 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149496-A1 INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL KCNN3, CACNA1I, KCNN1 KCNA5 67/4885KCNK3 18/4885KCNK5 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.